JP2020508985A5 - - Google Patents

Download PDF

Info

Publication number
JP2020508985A5
JP2020508985A5 JP2019543376A JP2019543376A JP2020508985A5 JP 2020508985 A5 JP2020508985 A5 JP 2020508985A5 JP 2019543376 A JP2019543376 A JP 2019543376A JP 2019543376 A JP2019543376 A JP 2019543376A JP 2020508985 A5 JP2020508985 A5 JP 2020508985A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
dendrimer
formula
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019543376A
Other languages
English (en)
Japanese (ja)
Other versions
JP7074761B2 (ja
JP2020508985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/054420 external-priority patent/WO2018154004A1/en
Publication of JP2020508985A publication Critical patent/JP2020508985A/ja
Publication of JP2020508985A5 publication Critical patent/JP2020508985A5/ja
Application granted granted Critical
Publication of JP7074761B2 publication Critical patent/JP7074761B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019543376A 2017-02-22 2018-02-22 治療用デンドリマー Expired - Fee Related JP7074761B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762461983P 2017-02-22 2017-02-22
US62/461,983 2017-02-22
US201762488151P 2017-04-21 2017-04-21
US62/488,151 2017-04-21
US201762591823P 2017-11-29 2017-11-29
US62/591,823 2017-11-29
PCT/EP2018/054420 WO2018154004A1 (en) 2017-02-22 2018-02-22 Therapeutic dendrimers

Publications (3)

Publication Number Publication Date
JP2020508985A JP2020508985A (ja) 2020-03-26
JP2020508985A5 true JP2020508985A5 (enExample) 2021-03-11
JP7074761B2 JP7074761B2 (ja) 2022-05-24

Family

ID=61386833

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019543376A Expired - Fee Related JP7074761B2 (ja) 2017-02-22 2018-02-22 治療用デンドリマー

Country Status (23)

Country Link
US (4) US10314920B2 (enExample)
EP (1) EP3585441A1 (enExample)
JP (1) JP7074761B2 (enExample)
KR (2) KR102544033B1 (enExample)
CN (2) CN117582521A (enExample)
AU (1) AU2018223149B2 (enExample)
BR (1) BR112019016409A2 (enExample)
CA (1) CA3053069A1 (enExample)
CL (1) CL2019002240A1 (enExample)
CO (1) CO2019009722A2 (enExample)
CR (1) CR20190361A (enExample)
DO (1) DOP2019000204A (enExample)
EC (1) ECSP19056271A (enExample)
IL (1) IL268648B (enExample)
JO (1) JOP20190191B1 (enExample)
MX (1) MX2019009442A (enExample)
NI (1) NI201900088A (enExample)
PE (1) PE20191660A1 (enExample)
PH (1) PH12019501896A1 (enExample)
SG (1) SG11201907334QA (enExample)
TW (1) TWI773730B (enExample)
UA (1) UA125655C2 (enExample)
WO (1) WO2018154004A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
TWI856967B (zh) 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
KR102948775B1 (ko) * 2018-11-20 2026-04-03 스타파마 피티와이 리미티드 치료 덴드리머
WO2020225307A1 (en) 2019-05-07 2020-11-12 Syddansk Universitet Mechanism for dispensing biological material
EP4034169B1 (en) * 2019-09-26 2026-02-11 Starpharma Pty Limited Therapeutic dendrimer
US20210170040A1 (en) * 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
PH12022552818A1 (en) 2020-04-24 2024-03-25 Ashvattha Therapeutics Inc Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
WO2021213492A1 (zh) * 2020-04-24 2021-10-28 上海森辉医药有限公司 一类载药的大分子及其制备方法
BR112023000320A2 (pt) * 2020-07-10 2023-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso
BR112023002855A2 (pt) 2020-08-25 2023-04-25 Shanghai Senhui Medicine Co Ltd Macromolécula carregada com fármaco e método de preparação para a mesma
EP4203968A4 (en) * 2020-08-31 2025-07-30 Starpharma Pty Ltd DENDRIMER-DRUG CONJUGATE

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4289872A (en) * 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4410688A (en) * 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
ES2625109T3 (es) * 2005-10-25 2017-07-18 Starpharma Pty Limited Compuestos macromoleculares que tienen estequiometría controlada
JP5989294B2 (ja) 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ 修飾高分子
WO2008017122A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Polylysine dendrimer contrast agent
US8420067B2 (en) * 2006-08-11 2013-04-16 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
EP2094672B1 (en) 2006-11-15 2013-05-29 Genentech, Inc. Arylsulfonamide compounds
US9283302B2 (en) 2011-12-16 2016-03-15 Cormatrix Cardiovascular, Inc. Extracellular matrix encasement structures and methods
WO2009036035A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
ES2672526T3 (es) 2008-06-26 2018-06-14 Prolynx Llc Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
US8216549B2 (en) * 2008-07-25 2012-07-10 National Health Research Institutes Method for making a ligand-quantum dot conjugate
DK2376480T3 (en) 2008-12-05 2016-09-12 Abbvie Inc Sulfonamide derivatives AS BCL-2-selective apoptosis inducing agents for the treatment of cancer and immune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010138588A2 (en) 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI471321B (zh) 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
WO2011046842A1 (en) * 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
IN2014DN00101A (enExample) * 2011-06-06 2015-05-15 Starpharma Pty Ltd
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates
US10730999B2 (en) * 2014-06-06 2020-08-04 Starpharma Pty Ltd Dendrimer-drug conjugates
TWI773730B (zh) * 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
TWI856967B (zh) * 2018-08-17 2024-10-01 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法

Similar Documents

Publication Publication Date Title
JP2020508985A5 (enExample)
KR100559068B1 (ko) 캄프토테신 유도체, 이의 중합체성 복합체, 이들의 제조방법 및 이들을 함유하는 약제학적 조성물
JP2008536807A5 (enExample)
US20200297693A1 (en) Glucose conjugates of triptolide, analogs and uses thereof
CA3025931A1 (en) Antibody drug conjugates having derivatives of amatoxin as the drug
RU2011118055A (ru) Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
KR20210034011A (ko) 치료 덴드리머
JP2008542399A5 (enExample)
US6376617B1 (en) Bioactive derivatives of camptothecin
RU2130941C1 (ru) Трехъядерные катионные комплексы платины, проявляющие противоопухолевую активность, способ их получения и фармацевтические композиции, содержащие эти комплексы
CA2396702A1 (en) N,o-amidomalonate platinum complexes
EP2737896B1 (en) Umirolimus micelle for the treating cancer
JP7506659B2 (ja) 癌を処置する方法に用いられるコンジュゲート
WO2014084378A1 (ja) 環状ｒｇｄ配列含有ペプチドを含む抗癌剤
WO2005079396A2 (en) O,o'-amidomalonate and n,o-amidomalonate platinum complexes
JP2008504235A5 (enExample)
CA3126574C (en) Cd44 targeted multi-arm conjugate
TW201004631A (en) Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
KR102138415B1 (ko) 신규 peg 유도체
CA2542007A1 (en) Protein tyrosine kinase inhibitors
HRP20100301T1 (hr) Ciklopeptidni derivati sa anti-integrinskom aktivnošću
CN108697696B (zh) 抗肿瘤剂
JP6996816B2 (ja) 医薬化合物
JP2021527123A (ja) 環状ペプチド化合物およびその使用方法
EP3747909B1 (en) Anticancer agent